跳至主要内容
临床试验/NCT06390592
NCT06390592尚未招募不适用

Clinical Performance of the Therapy Option FlexPoint (Flexible Volume and Dwell Time Management) of the PD Cycler Sleep•Safe Harmony

Fresenius Medical Care Deutschland GmbH0 个研究点目标入组 24 人开始时间: 2026年12月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
24
主要终点
Total Kt/V urea

研究概览

简要总结

Analysis and comparison of treatments with and without the FlexPoint technology (flexible volume and dwell time management) of the PD cycler sleep•safe harmony

详细描述

The primary objective of this study are:

  • to investigate and compare the clinical performance of standard (default) FlexPoint settings to minimum FlexPoint settings and to the maximum value for permitted peritoneal residual volume of FlexPoint settings of the PD cycler sleep•safe harmony in the treatment of PD patients.
  • to assess whether usage of the settings of the therapy option FlexPoint (flexible volume and dwell time management) of the PD cycler sleep•safe harmony that deviate from the system default and from former sleep•safe settings, influences the efficacy of APD treatments as well as the hydration status (by using BCM) of PD patients.

The secondary objectives of this study are:

  • Patients´ Quality of Life (QoL)
  • Number of alarms
  • To investigate the effects on solute removal
  • To investigate the tolerability of the FlexPoint therapy options
  • Adverse events / SAE

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent signed and dated by study patient and investigator/ authorised physician
  • Minimum age of 18 years
  • CKD patients with indication for renal replacement therapy
  • Patients being treated with APD for at least 3 months
  • Patients using the sleep•safe harmony PD cycler (version 3.1)
  • Fluid status regularly monitored with Body Composition Monitor (BCM)
  • Proper functioning catheter
  • Intraperitoneal Pressure (IPP) ≤ 18 cm H2O
  • Ability to understand the nature and requirements of the study

排除标准

  • Any conditions which could interference with the patient's ability to comply with the study
  • Previous participation in the same study
  • Patients who have any condition prohibiting the use of BCM, like patients with major amputations (e.g. lower leg)
  • Patients receiving polyglucose containing PD solution
  • Respiratory or abdominal wall disease deemed to contraindicate intraperitoneal fill volume (FV) manipulation
  • Patients who suffer from peritonitis/exit site infection during the last 4 weeks
  • Women of childbearing age without effective means of contraception, pregnancy (pregnancy test will be conducted at start and end of study) or lactation period
  • Life expectancy <3 months
  • Participation in an interventional clinical study during the preceding 90 days

研究组 & 干预措施

Peritoneal dialysis (PD)

Other

During the clinical phase, patients are treated continuously with the PD cycler sleep•safe harmony.

The total duration of the clinical phase is six weeks and is divided into 3 Phases à 2 weeks (Clinical phase I, II, and III) which only differ in the FlexPoint settings.

According to their randomization the patients are treated with Treatment A, B or C in a different order:

  • standard (default) FlexPoint settings (Treatment A)
  • minimum value FlexPoint settings (Treatment B)
  • maximum value for permitted peritoneal residual volume (50%) of FlexPoint settings (Treatment C)

干预措施: PD cycler (Device)

结局指标

主要结局

Total Kt/V urea

时间窗: every 2 weeks, during the 6 weeks treatment

Measurement of solute removal during peritoneal dialysis focuses on urea

次要结局

  • Mean daily ultrafiltration (UF)(every day, during the 6 weeks treatment)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验